Most Popular
-
1
IMF lowers Korea's 2025 growth outlook to 2%
-
2
Reality show 'I Live Alone' disciplined for 'glorifying' alcohol consumption
-
3
Now is no time to add pressure on businesses: top executives
-
4
CJ CheilJedang to spur overseas growth with new Hungary, US plants
-
5
Japan to hold 1st memorial for Korean forced labor victims at Sado mine
-
6
[Herald Interview] How Gopizza got big in India
![[Herald Interview] How Gopizza got big in India](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/20/20241120050057_0.jpg&u=20241120164556)
-
7
Nearly half of pines at Seoraksan face extinction due to global warming: study
-
8
Blackpink's solo journeys: Complementary paths, not competition
-
9
Nationwide rail disruptions feared as union plans strike from Dec. 5
-
10
S. Korea sees second-highest immigration surge in OECD
![[Herald Interview] How Gopizza got big in India](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/20/20241120050057_0.jpg&u=20241120164556)
[THE INVESTOR] Alpha Holdings announced on Oct. 13 that it has acquire additional stake in the US-based immunity anti-cancer medicine firm Viral Gene.
Including the stake held by its subsidiary Alpha Biolabs, Alpha Holding’s is now the US-based company’s largest shareholder with 37.64 percent stake.
Alpha Holdings acquired Viral Gene shares held by TJU Asset Management and Penn Life Science, which each acquired 1.66 percent of its shares.
Viral Gene is currently developing a treatment for colorectal cancer, and plans to begin phase 2 clinical trials within the year.
By Choi He-suk (cheesuk@heraldcorp.com)
Including the stake held by its subsidiary Alpha Biolabs, Alpha Holding’s is now the US-based company’s largest shareholder with 37.64 percent stake.
Alpha Holdings acquired Viral Gene shares held by TJU Asset Management and Penn Life Science, which each acquired 1.66 percent of its shares.
Viral Gene is currently developing a treatment for colorectal cancer, and plans to begin phase 2 clinical trials within the year.
By Choi He-suk (cheesuk@heraldcorp.com)
